Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer

Şükrü Tüzmen (Corresponding Author), Galen Hostetter, Aprill Watanabe, Cumhur Ekmekçi, Patricia E. Carrigan, Ishaiahu Shechter, Olli Kallioniemi, Laurence J. Miller, Spyro Mousses

Research output: Contribution to journalArticleScientificpeer-review

19 Citations (Scopus)


Aim: To help characterize the FDFT1 gene and protein expression in cancer. Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.
Original languageEnglish
Pages (from-to)51-65
Number of pages15
JournalPersonalized Medicine
Issue number1
Publication statusPublished - Jan 2019
MoE publication typeA1 Journal article-refereed


  • cancer
  • cholesterol
  • FDFT1
  • gene expression
  • immunohistochemistry
  • lipidrafts
  • microdomains
  • plasma membrane
  • qPCR
  • TMA


Dive into the research topics of 'Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer'. Together they form a unique fingerprint.

Cite this